CurrentEndo
Get Weekly

Topic · page 4 of 12

Lipids & metabolic liver disease

Lipid disorders and metabolic dysfunction-associated steatotic (fatty) liver disease, as published in the endocrine journals

Briefs 121–160 of 460 placed here, newest publication first

Briefs in Lipids & metabolic liver disease

Newest publication first

  1. Pediatr Obes

    Starting Age for Screening Metabolic Dysfunction‐Associated Steatotic Liver Disease in Children Using Controlled Attenuation Parameter on Transient Elastography

    Cross-sectional study

  2. Lancet Diabetes Endocrinol

    Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial

    Randomized controlled trial

  3. Diabetes Obes Metab

    Associations between steatotic liver disease subtypes and incident diabetes in young Korean adults: A nationwide cohort study

    Cohort study

  4. Cardiovasc Diabetol

    Proteomic signature of metabolic dysfunction-associated steatotic liver disease and risk of atherosclerotic cardiovascular disease

    Cohort study

  5. Cardiovasc Diabetol

    Combined association of triglyceride-glucose index and the atherogenic index of plasma with the incidence of cardiovascular diseases among middle-aged and older population

    Cohort study

  6. Diabetes Obes Metab

    Meta‐analysis of clinically available pharmacotherapy of biopsy confirmed metabolic dysfunction associated steatohepatitis ( MASH )

    Meta-analysis

  7. Clin Endocrinol (Oxf)

    Evaluation of a Fixed‐Dose Insulin Protocol for Hypertriglyceridemia‐Induced Acute Pancreatitis: A Retrospective Cohort Study

    Cohort study

  8. Diabetes Obes Metab

    Efficacy and safety of liraglutide in non‐alcoholic fatty liver disease with or without type 2 diabetes: A systematic review and meta‐analysis

    Meta-analysis

  9. Diabetes Obes Metab

    Association of cumulative exposure to cholesterol, high‐density lipoprotein, and glucose index with the risk of cardiovascular disease and all‐cause mortality: A longitudinal cohort study

    Cohort study

  10. Cardiovasc Diabetol

    Interplay among lipoprotein(a), hepatic and vascular damage in individuals with metabolic dysfunction

    Cohort study

  11. Diabetes Obes Metab

    Obicetrapib for dyslipidemia with or without cardiovascular risk: A GRADE ‐assessed meta‐analysis of randomized trials with trial sequential evidence

    Meta-analysis

  12. Cardiovasc Diabetol

    Association between the atherogenic index of plasma and major adverse cardiovascular events in individuals with metabolic syndrome: findings from the UK biobank

    Cohort study

  13. Diabetes Res Clin Pract

    Rising burden of metabolic dysfunction-associated steatotic liver disease in adolescents aged 15–19 years and projections to 2035

    Research article

  14. Diabetes Res Clin Pract

    Liver fat accumulation within the ‘normal range’ is associated with the presence of metabolic syndrome traits

    Cross-sectional study

  15. Cardiovasc Diabetol

    Elevated triglyceride-glucose index and its combination with anthropometric indices as indicators of the risk of new-onset transient ischemic attack: a prospective cohort study

    Cohort study

  16. Cardiovasc Diabetol

    Associations between triglyceride-glucose-related indices and all-cause and cardiovascular mortality among individuals with atrial fibrillation and metabolic syndrome: a cohort study of the UK biobank

    Cohort study

  17. J Clin Endocrinol Metab

    Diurnal Light Exposure and Rest-Activity Rhythms in Relation to MASLD: Insights From 2 Nationwide Cohort Studies

    Cohort study

  18. Cardiovasc Diabetol

    The prognostic value of atherogenic index of plasma and thin-cap fibroatheroma among patients with STEMI: an optical coherence tomography prospective cohort study of real world

    Cohort study

  19. Cardiovasc Diabetol

    Safety, pharmacokinetics and pharmacodynamics of Plozasiran in Chinese healthy volunteers

    Randomized controlled trial

  20. Cardiovasc Diabetol

    The role of insulin resistance in the longitudinal progression from NAFLD to cardiovascular-kidney-metabolic disease

    Cohort study

  21. Cardiovasc Diabetol

    Association between atherogenic index of plasma (AIP) and all-cause and cardiovascular mortality in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): a cohort study based on NHANES 1999–2018

    Cohort study

  22. Diabetes Care

    Relationship Between Metabolic and Histological Responses in People With Metabolic Dysfunction– Associated Steatohepatitis With and Without Type 2 Diabetes: Participant-Level Exploratory Analysis of the SYNERGY-NASH Trial With Tirzepatide

    Secondary analysis

  23. Diabetes Obes Metab

    Histological efficacy of anti‐diabetic agents in MASH and the mediating role of weight loss: A network meta‐analysis

    Meta-analysis

  24. J Clin Endocrinol Metab

    Serum Proteomics of Insulin Resistance Disorders Distinguish MASLD From Lipodystrophy and Insulin Receptor Defects

    Mechanistic study

  25. Cardiovasc Diabetol

    Dual modulation of lipid and glucose metabolism by a nutraceutical combination in patients at cardiometabolic risk: results from a multicenter randomized controlled trial

    Secondary analysis

  26. Endocr Pract

    Reliable Monitoring of Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease Using Imaging: A Systematic Literature Review and Meta-Analysis on Measurement Repeatability

    Meta-analysis

  27. Cardiovasc Diabetol

    Effect of changes in the triglyceride-glucose index on atherogenic lipid profiles in coronary artery disease patients receiving lipid-lowering therapy: a prospective cohort study

    Cohort study

  28. Cardiovasc Diabetol

    Relation of the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio to residual risk in anticoagulated patients with atrial fibrillation: a report from the prospective Murcia AF Project III cohort

    Cohort study

  29. Diabetes Obes Metab

    An interpretable machine learning model for predicting metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes

    Cohort study

  30. Obesity (Silver Spring)

    Genetic Determinants of Fatty Acid Composition in Subcutaneous and Visceral Adipose Tissue

    Research article

  31. Diabetes Res Clin Pract

    End-stage renal diseases associated with SGLT2 inhibitors versus GLP-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease

    Cohort study

  32. Endocr Pract

    American Association of Clinical Endocrinology Consensus Statement: Algorithm for Management of Adults with Dyslipidemia – 2025 Update

    Guideline or statement

  33. Diabetes Obes Metab

    Investigating multimorbidity trajectories in people living with MASLD diagnosis: A trajectory analysis using the UK Biobank

    Cohort study

  34. Diabetes Obes Metab

    Relationship of intra‐pancreatic fat deposition with low‐density lipoprotein subfractions and hepatic lipase

    Cross-sectional study

  35. Cardiovasc Diabetol

    Associations between steatotic liver disease subtypes and incident atrial fibrillation in young adults: a nationwide cohort study

    Cohort study

  36. Int J Obes (Lond)

    Diurnal timing and volume of physical activity in relation to metabolic syndrome in US adults: a population-based cohort study

    Cohort study

  37. J Clin Endocrinol Metab

    Magnesium Depletion, Metabolic Impairment, and Cardiac Alterations: The NAKO-MRI Study With Mendelian Randomization

    Cross-sectional study

  38. Diabetes Res Clin Pract

    Association of chronic kidney disease and type 2 diabetes mellitus with metabolic dysfunction-associated steatotic liver disease and liver fibrosis assessed by transient elastography: a cross-sectional study based on NHANES 2017–2020

    Cross-sectional study

  39. Diabetes Obes Metab

    Association of GLP1 ‐receptor agonist use with liver disease progression, major cardiovascular events, and mortality in people with hepatic steatosis and diabetes

    Cohort study

  40. Cardiovasc Diabetol

    Derivatives of the triglyceride–glucose index and their association with incident hypertension in prehypertensive individuals: a 4-year cohort study augmented by mendelian randomization

    Cohort study

All 460 Briefs in ExploreShowing Briefs 121–160 of 460, newest first